Author

Òscar Palacios

Universitat Autònoma de BarcelonaORCID 0000-0002-2987-7303Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Evolutionary Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:human· 1 Organism:non-human primate· 1 Research Focus:phylogenetics / evolution· 1

Frequent Co-Authors

A. ConstantinescuiD· 1 shared Akinchan Kumar· 1 shared Axelle BerrouiD· 1 shared Bassam JanjiiD· 1 shared Delphine Colignon· 1 shared Guillaume MartiniD· 1 shared Guy FournetiD· 1 shared Ismail Ceylan· 1 shared

Activity by Year

2024-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 36 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. ConstantinescuORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

THE EVOLUTIONARY HISTORY OF METALLOTHIONEINS IN HORSESHOE CRABS, SCORPIONS, SPIDERS AND OTHER CHELICERATE SPECIES.

Òscar Palacios, Mercè Capdevila, Ricard Albalat

This study identifies and classifies over 400 metallothioneins (MTs) in chelicerates, revealing three types with distinct structural and evolutionary features.

Scientific Reports · Mar 24, 2026Peer-reviewedEvolutionary Biology

ALDH1 subtype-specific inhibitor targets key cancerous epithelial cell populations in aggressive subtypes of breast cancer

Raquel Pequerul, A. Constantinescu, Bassam Janji, Akinchan Kumar, Xavier Parés, Òscar Palacios, Delphine Colignon, Axelle Berrou, Guy Fournet, Paul BERCHARD, Guillaume Martin, Ismail Ceylan, Rocio Rebollido-Ríos, Jaume Farrés, Mileidys Perez-Alea

This study identifies ALDH1A3 as a therapeutic target in aggressive breast cancers and develops ABD0171, a selective inhibitor showing antitumor and antimetastatic effects.

bioRxiv · Oct 18, 2024 · PreprintCancer Biology